FDA Approves Xopenex Metered-Dose Inhaler
Marlborough, Mass. The Food and Drug Administration has approved Sepracor’s drug application for an inhaler version of Xopenex. The inhalation solution
Marlborough, Mass.
The Food and Drug Administration has approved Sepracor’s drug application for an inhaler version of Xopenex. The inhalation solution is currently available for use in a nebulizer to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease. Sepracor plans to launch the metered-dose inhaler version, Xopenex HFA, around the end of the year.
OUR DIGITAL PARTNERS
RELATED ARTICLES
How Passive Monitoring Can Help Keep Homecare Patients Safe
Remote patient monitoring helps improve outcomes for seniors between visits
Addressing the Lack of Homes in Home Health
Why affordable housing is a healthcare issue
The Real Challenge After Diversifying Your Home Health Offerings
Integration is becoming the next competitive advantage in homecare
There is a Cure for the Elder Care Staffing Crisis
Why visa-based international hiring should be part of your staffing strategy